Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATM-AVI vs meropenem for serious gram-negative infections
CTR20182092Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of aztreonam + avibactam in Intra-abdominal infection (IAI), hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), Infection due to metallo-beta-lactamase-producing Gram-negative bacteria, sponsored by Pfizer. Started Sep 2019; status: completed.
02
Drugs
aztreonam + avibactam
03
Conditions
Intra-abdominal infection (IAI)hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Infection due to metallo-beta-lactamase-producing Gram-negative bacteria
Beyond the preview
Go deeper on CTR20182092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182092.